JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials.
about
Molecular classification of gastric cancer: Towards a pathway-driven targeted therapyNovel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patientsThe tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD miceJanus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancerJAK and MPL mutations in myeloid malignancies.Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent years.Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.Advances in understanding the pathogenesis of primary familial and congenital polycythaemiaLestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosisRearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemiaReciprocal regulation of c-Src and STAT3 in non-small cell lung cancer.JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase.Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators.Blockade of Janus kinase-2 signaling ameliorates mouse liver damage due to ischemia and reperfusionRed blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS.Modest activity of pomalidomide in patients with myelofibrosis and significant anemiaSequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.Chronic myeloproliferative neoplasms: a collaborative approach.Beyond the 2008 World Health Organization classification: the role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemiaA CK2-dependent mechanism for activation of the JAK-STAT signaling pathway.Signal transducer and activator of transcription 5a/b: biomarker and therapeutic target in prostate and breast cancerThe JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.The two faces of Janus kinases and their respective STATs in mammary gland development and cancerGenetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibitionComparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disordersJAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin.Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues.Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases
P2860
Q26798420-DFC9CF6A-F0A9-448E-975B-21097A863D17Q27687464-0C5BF859-3059-40B4-A79C-163E84A4D68BQ28238474-A09AC962-1EFB-45A6-A4C7-DE1CF4F59027Q28483660-34010952-55EE-4C62-A5E1-5459D80D9C22Q28588240-2C089E99-7D49-4D32-8518-24F2FBC0ADEBQ33378737-107076C8-313E-4242-8B20-3C1E2AD22707Q33392291-0C0B927B-19A3-4897-A898-ABD83CBEEBD8Q33517074-A4FEB281-A541-4076-8399-441DF57A67B2Q33586552-061BA123-6FA5-4926-BDAC-BF0A072C5254Q33753094-4E318636-EE5C-4CA0-A00C-B87D92A216A1Q33828925-493FF7F0-423F-4C2D-AF1C-4A669105A14AQ33886243-3122A188-9E9F-4F27-B8E5-7D2C919CC60DQ33985127-F14DF11F-A47C-4A4F-84AB-C14495E3373BQ34109397-0874058A-556B-4C9C-A2E0-021595F326CEQ34150008-D025BB14-528C-4B69-9C1E-1BB6A2B2D981Q34162867-C160DC12-D334-4AE8-B923-9212F9DA3319Q34169114-42F9BB39-6529-4A36-9537-802A2F3D84C8Q34182738-0BBF10D9-CB62-46BB-A555-C71C99010B79Q34294698-4F2DEE36-9118-46EC-A1AB-CE515B35B4B0Q34402761-480BDB27-EB89-44A9-9D3B-63C9A9F7F782Q34451630-4C0D5678-C1E0-4D1D-B768-6CB8E49B427BQ34512203-8492D9BD-252D-4757-9333-BCF60284FAD0Q34541582-A5AC8B6B-2068-4114-810E-123DCB71C769Q34549335-0C1E383A-B41E-46FF-959D-67CFFF6EC283Q34755687-755C23C0-A7E8-45B3-A010-D4485609C6A7Q35114492-EDA82BC5-DE6E-469E-90A4-DBAEEA293E35Q35186472-EB259208-F197-4C35-A3DE-B81A7AE8772CQ35572396-A35E0F60-EFA8-4451-8F25-F1DF35CE1AE3Q35685851-94D3593B-A557-4EE6-98B5-1612DF1BEB6CQ35760845-2DC75577-8D08-405F-B1DC-E24C924BD16CQ36374813-2CF7825C-986F-48E7-AD66-BE2FFEA2486DQ36612537-8C0E1B43-C6BF-4866-B4FA-BAC173400A44Q37109225-85039296-D2CD-4119-ADFB-86386BA3BB03Q37170349-49AEE05A-672A-40CA-8211-2C50965EBF61Q37191213-60F2B85C-9EDB-4A4F-9F84-B9C2DC2F6E2CQ37310619-2A7A7B63-D854-4768-9A9B-59A7ED465D87Q37379320-2921225B-AFD4-4280-B2F0-091C273D9E8DQ37460337-6785F7AF-FE3D-4238-8032-FBAC275E2E13Q37566249-9381683D-B88E-45D1-9BE0-28BE7AA33939Q37687519-48967A40-4D88-4075-A3F5-F0ABE09F6189
P2860
JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
JAK2 inhibitor therapy in myel ...... s and ongoing clinical trials.
@en
type
label
JAK2 inhibitor therapy in myel ...... s and ongoing clinical trials.
@en
prefLabel
JAK2 inhibitor therapy in myel ...... s and ongoing clinical trials.
@en
P356
P1433
P1476
JAK2 inhibitor therapy in myel ...... s and ongoing clinical trials.
@en
P2093
Pardanani A
P2888
P356
10.1038/SJ.LEU.2404948
P577
2007-09-20T00:00:00Z